News Category Search | MedStar Health

Featured News

  • November 30, 2021

    Washington, D.C., November 30, 2021 – MedStar Heart & Vascular Institute physicians at MedStar Washington Hospital Center have completed their 300th implant of the HeartMate 3 Left Ventricular Assist Device (LVAD), which treats patients with advanced heart failure. MedStar Washington is among the first four LVAD programs nationwide to reach this historic milestone.

    MedStar Washington Hospital Center participated in the MOMENTUM 3 clinical trial and its post-pivotal study Continuous Access Protocol (CAP), testing the efficacy of the HeartMate 3 LVAD for safety and sustainability as short- and long-term support for patients with advanced (stage D) heart failure. The FDA approved the HeartMate 3 device as a bridge-to-transplant, or as destination therapy treatments. As a result of the trials, the HeartMate 3 pump became the most-often used LVAD therapy with high success rates and lower complication rates.

    “Over the last two decades, LVADs have revolutionized the way we treat patients with stage D heart failure. With a modern technological design that includes full magnetic levitation of the impeller, this pump represents the best LVAD our field has ever seen,” said Ezequiel Molina, MD, surgical director of the Advanced Heart Failure Program at MedStar Washington Hospital Center. “The HeartMate 3 device is a small, more portable and quieter LVAD than previous generations. Patients enjoy longer survival, experience fewer complications, and return to a fairly active lifestyle. And that is our goal – to improve the quality of life of our patients.”

    Many heart failure patients rely on LVADs, which are heart mechanical support devices that can keep blood pumping throughout the body when medications are no longer effective. LVADs can mean the difference between life and death for patients whose hearts are too weak to pump blood adequately on their own. These devices are an effective option as a patient waits for a heart transplant or as long-term treatment.

    MedStar Washington Hospital Center is one of the most experienced LVAD programs in the country, implanting more than 80 devices each year. It has been at the forefront of all the major clinical trials to test new devices. In 1988, it became one of the first four hospitals in the world to implant this potentially game-changing technology in mechanical circulatory support. To date, MedStar Washington has successfully implanted more than 800 VADs.

     


    MedStar Washington Hospital Center is a not-for-profit, 912-bed, teaching and research hospital in the nation’s capital, and is a major referral center for treating the region’s most complex cases. Its cardiology program is highly acclaimed, and its cardiac surgery program has consistently earned the highest national rating–three stars–from the Society of Thoracic Surgeons. MedStar Washington operates the region’s first Comprehensive Stroke Center and the District’s only Cardiac Ventricular Assist Device program, both certified by The Joint Commission. The hospital is also home to MedSTAR, a nationally verified level I trauma center with a state-of-the-art fleet of helicopters and ambulances, and also operates the region’s only adult Burn Center.

Share this

MedStar Health makes the news

All News

  • November 30, 2021

    Washington, D.C., November 30, 2021 – MedStar Heart & Vascular Institute physicians at MedStar Washington Hospital Center have completed their 300th implant of the HeartMate 3 Left Ventricular Assist Device (LVAD), which treats patients with advanced heart failure. MedStar Washington is among the first four LVAD programs nationwide to reach this historic milestone.

    MedStar Washington Hospital Center participated in the MOMENTUM 3 clinical trial and its post-pivotal study Continuous Access Protocol (CAP), testing the efficacy of the HeartMate 3 LVAD for safety and sustainability as short- and long-term support for patients with advanced (stage D) heart failure. The FDA approved the HeartMate 3 device as a bridge-to-transplant, or as destination therapy treatments. As a result of the trials, the HeartMate 3 pump became the most-often used LVAD therapy with high success rates and lower complication rates.

    “Over the last two decades, LVADs have revolutionized the way we treat patients with stage D heart failure. With a modern technological design that includes full magnetic levitation of the impeller, this pump represents the best LVAD our field has ever seen,” said Ezequiel Molina, MD, surgical director of the Advanced Heart Failure Program at MedStar Washington Hospital Center. “The HeartMate 3 device is a small, more portable and quieter LVAD than previous generations. Patients enjoy longer survival, experience fewer complications, and return to a fairly active lifestyle. And that is our goal – to improve the quality of life of our patients.”

    Many heart failure patients rely on LVADs, which are heart mechanical support devices that can keep blood pumping throughout the body when medications are no longer effective. LVADs can mean the difference between life and death for patients whose hearts are too weak to pump blood adequately on their own. These devices are an effective option as a patient waits for a heart transplant or as long-term treatment.

    MedStar Washington Hospital Center is one of the most experienced LVAD programs in the country, implanting more than 80 devices each year. It has been at the forefront of all the major clinical trials to test new devices. In 1988, it became one of the first four hospitals in the world to implant this potentially game-changing technology in mechanical circulatory support. To date, MedStar Washington has successfully implanted more than 800 VADs.

     


    MedStar Washington Hospital Center is a not-for-profit, 912-bed, teaching and research hospital in the nation’s capital, and is a major referral center for treating the region’s most complex cases. Its cardiology program is highly acclaimed, and its cardiac surgery program has consistently earned the highest national rating–three stars–from the Society of Thoracic Surgeons. MedStar Washington operates the region’s first Comprehensive Stroke Center and the District’s only Cardiac Ventricular Assist Device program, both certified by The Joint Commission. The hospital is also home to MedSTAR, a nationally verified level I trauma center with a state-of-the-art fleet of helicopters and ambulances, and also operates the region’s only adult Burn Center.

  • September 14, 2021

    WASHINGTON– Two MedStar Health hospitals are now offering an FDA-approved treatment for patients who have had persistent atrial fibrillation for more than a year. The Hybrid AF™ Convergent Therapy is available both at MedStar Washington Hospital Center and MedStar Union Memorial Hospital in Baltimore. MedStar Health physicians participated in the landmark CONVERGE™ trial, which provided the key data for FDA approval of this treatment in April 2021.

    Atrial fibrillation, or AFib, is an irregular heartbeat that occurs when a heart has lost its healthy rhythm. If not properly treated, AFib can lead to blood clots, stroke, other heart-related complications, and even sudden death.

    Long-standing, persistent atrial fibrillation (LSPAF) is a particularly challenging form of this condition to treat. Some 45 percent of AFib patients cope with LSPAF, so the Hybrid AF Convergent Therapy is a breakthrough treatment for those with long-standing, persistent AFib.

    “Historically, patients with LSPAF have been challenging to treat, and about half suffer from progressively worsening symptoms,” said Zayd Eldadah, MD, PhD, director of Cardiac Electrophysiology at MedStar Washington Hospital Center. “This hybrid procedure will help improve the lives of millions of patients with severe AFib, and we are thrilled that we now have a new arsenal in our toolbox to treat what was once a very difficult disease.”

    The Hybrid AF Convergent Therapy is a minimally invasive, two-part ablation procedure that uses heat to stop the erratic electrical signals that cause AFib and restore a normal heart rhythm. A cardiac surgeon performs the first procedure by making a small incision under the breastbone, to create access to the heart and then creates lesions or scar tissue on the back walls of the heart. An electrophysiologist then gains access to the inside of the heart and blood vessels through the groin, to deliver therapeutic energy to areas of the heart to destroy the abnormal electrical activity.

    “There have been less than optimal outcomes for a population of Afib patients who simply don’t respond as we would like to after endocardial ablation alone,” said Brian Bethea, MD, chief of Cardiac Surgery at MedStar Union Memorial Hospital. “This is the kind of technology we looked to the future for, and now it’s available. This is a double procedure we feel confident in offering our patients with persistent Afib, where the incisions are small, the hospital stay and recovery times are shorter and most importantly, the success rate is high.”

    MedStar Health has offered convergent therapy for the last decade, and the recent FDA approval has moved the Hybrid AF™ Convergent Therapy to the forefront of treatment options.

    AFib is the most common arrhythmia in the U.S. with one out of four adults over 40 developing AFib in their lifetime.  

  • July 27, 2021

    Only Nationally Ranked Heart Program in the Washington Region

    Washington, D.C. – Once again, MedStar Washington Hospital Center has been recognized among the nation’s top cardiac centers in the 2021-22 U.S. News & World Report “Best Hospitals” rankings. Its Cardiology and Heart Surgery program climbed to No. 30, up seven from last year’s survey. It is the only nationally recognized heart program of its kind in the Washington region. MedStar Washington also received the highest rating possible in aortic valve surgery, heart attack, heart bypass surgery, heart failure, and transcatheter aortic valve replacement (TAVR).

    U.S. News evaluated more than 4,750 medical centers nationwide in 15 specialties and 17 procedures and conditions. In the 15 specialty areas, 175 hospitals were ranked in at least one specialty.

    “Our continuing and ascending stature amongst the best regarded cardiovascular centers in the country is a tribute to the tireless teamwork and dedication of our physicians and associates who strive to put the principle of keeping patients at the heart of everything they do,” said Stuart F. Seides, MD, physician executive director of the MedStar Heart & Vascular Institute. “And to all those patients and their physicians who entrust us with their care, we offer our most sincere gratitude.”

    MedStar Washington Hospital Center, home to MedStar Heart & Vascular Institute, has one of the highest-volume cardiac programs in the nation. It integrates the cardiovascular programs and services of all 10 MedStar Health hospitals and outpatient practices in Maryland, Virginia, and Washington, D.C. Its clinical and research alliance with Cleveland Clinic Heart, Vascular & Thoracic Institute, again ranked No. 1 in the nation by U.S. News, has continued to flourish since 2013.

    U.S. News also cited MedStar Washington’s Urology program as high-performing. Six other common procedures and conditions, chronic obstructive pulmonary disease (COPD), colon cancer surgery, diabetes, kidney failure, pneumonia, and stroke, received the highest ratings, too. "High Performing" is the highest rating U.S. News awards for these types of care that were significantly better than the national average, as measured by factors such as patient outcomes.

     The complete rankings are available at https://health.usnews.com/best-hospitals/rankings.

     

    MedStar Washington Hospital Center is a not-for-profit, 912-bed, teaching and research hospital in the nation’s capital, and is a major referral center for treating the region’s most complex cases. Its cardiology program is highly acclaimed, and its cardiac surgery program has consistently earned the highest national rating–three stars–from the Society of Thoracic Surgeons. MedStar Washington operates the region’s first Comprehensive Stroke Center and the District’s only Cardiac Ventricular Assist Device program, both certified by The Joint Commission. The hospital is also home to MedSTAR, a nationally verified level I trauma center with a state-of-the-art fleet of helicopters and ambulances, and also operates the region’s only adult Burn Center.

  • June 28, 2021
    MedStar Health is pleased to announce the establishment of the J.D. Murphy Jr. Cardio-Oncology Fellowship program at MedStar Washington Hospital Center.
  • November 12, 2020

    MedStar Washington Hospital Center First in D.C. and Central Maryland to Adopt HeartFlow Diagnostic Tool

    Washington D.C., – MedStar Washington Hospital Center became first in Washington, D.C. and central Maryland to adopt the HeartFlow® Analysis, a first-of-its-kind non-invasive technology to help physicians diagnose coronary artery disease (CAD), the most common form of heart disease.

    CAD is the leading cause of death for both men and women. It develops when cholesterol builds up in the arteries and blocks blood flow, causing chest pain or heart attacks.

    Many of the non-invasive tests available today have low accuracy rates in detecting CAD and studies have shown there is a need to improve how the disease is evaluated and diagnosed. A recent study found more than half of patients with suspected CAD who underwent an invasive coronary angiogram (ICA) had no need for intervention, since no blood flow-limiting blockage was found during the procedure.

    “Historically, cardiac CT has emerged as a powerful and accurate tool to detect coronary artery disease, but it has a limitation in that it cannot sometimes determine how significant of blockage the cholesterol buildup is causing in the arteries,” said Gaby Weissman, MD, section chief of Clinical Cardiology with MedStar Heart & Vascular Institute at MedStar Washington Hospital Center. “The HeartFlow Analysis changes this paradigm, allowing us to assess the coronary anatomy, blockages to the coronary arteries, and importantly, the physiological significance of those findings, all with one test. This provides essential information that can help us determine the right approach for a patient through a convenient, non-invasive platform.” 

    The HeartFlow Analysis takes the patient’s CT scans and creates a personalized 3D model of the patient’s coronary arteries. It then uses powerful computer algorithms to simulate blood flow and assess the extent and the impact of blockages on blood flow to the heart. This detailed information helps doctors determine the next steps in treatment for the patient.

    The HeartFlow Analysis has been used for over 60,000 patients with suspected heart disease. In clinical trials, using the HeartFlow Analysis helped identify which patients do and do not need invasive treatment.

    play button

    ###

    About MedStar Washington Hospital Center:
    MedStar Washington Hospital Center is a 912-bed, major teaching and research hospital. It is the largest private, not-for-profit hospital in the nation’s capital, among the 100 largest hospitals in the nation and a major referral center for treating the most complex cases. Its cardiology program is highly acclaimed and its cardiac surgery program has consistently earned the highest national rating–three stars–from the Society of Thoracic Surgeons. The Hospital Center operates the Washington region’s first Comprehensive Stroke Center and the District’s only Cardiac Ventricular Assist Device program, both certified by The Joint Commission. The hospital is also home to MedSTAR, a nationally verified level I trauma center with a state-of-the-art fleet of helicopters and ambulances, and also operates the region’s only adult Burn Center.

  • October 16, 2019
    Technology designed to enable early and accurate detection of lung nodules